Physician profile
Anna Kurayev
NPI 1952716177
$3,023.33
in general payments reported to CMS, 2019-2025
21 companies · $960 in 2025
The $960 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.00 · 2022: $642 · 2023: $649 · 2024: $701 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,280 · Education: $29.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,280.49 |
| Education | $29.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $441.56 | 2022-2025 | |
| Genzyme Corporation | $392.53 | 2022-2025 | |
| Janssen Biotech, INC. | $297.82 | 2019-2025 | Tremfya |
| Allergan, INC. | $232.26 | 2022 | |
| Pfizer INC. | $210.15 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $203.16 | 2022-2025 | Sotyktu |
| Incyte Corporation | $188.29 | 2022-2025 | Opzelura |
| Ucb, INC. | $180.29 | 2022-2025 | Bimzelx, Cimzia |
| Amgen INC. | $168.88 | 2022-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $146.46 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $141.90 | 2024-2025 | Dupixent |
| Almirall LLC | $83.61 | 2023-2025 | Seysara, Klisyri |
| Dermavant Sciences, INC. | $76.36 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $48.28 | 2024-2025 | Aklief, Oracea, Nemluvio |
| Journey Medical Corporation | $41.11 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $35.49 | 2022-2024 | |
| Leo Pharma INC. | $30.96 | 2022-2025 | Anzupgo |
| Organon LLC | $29.07 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.92 | 2024 | Spevigo |
| Lilly USA, LLC | $23.53 | 2022 | |
| Epi Health, LLC | $22.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Kurayev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.